Janux dives as gaps in prostate cancer study data worry investors

Core Viewpoint - Shares of Janux Therapeutics experienced a nearly 50% decline as investors expressed concerns over limited disclosure in the company's early-stage study update for its prostate cancer treatment [1] Company Summary - Janux Therapeutics' stock price fell by almost 50% on Tuesday, indicating significant investor reaction to the company's recent announcements [1]